1
|
Bhargavi G, Subbian S. The causes and consequences of trained immunity in myeloid cells. Front Immunol 2024; 15:1365127. [PMID: 38665915 PMCID: PMC11043514 DOI: 10.3389/fimmu.2024.1365127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Accepted: 03/28/2024] [Indexed: 04/28/2024] Open
Abstract
Conventionally, immunity in humans has been classified as innate and adaptive, with the concept that only the latter type has an immunological memory/recall response against specific antigens or pathogens. Recently, a new concept of trained immunity (a.k.a. innate memory response) has emerged. According to this concept, innate immune cells can exhibit enhanced responsiveness to subsequent challenges, after initial stimulation with antigen/pathogen. Thus, trained immunity enables the innate immune cells to respond robustly and non-specifically through exposure or re-exposure to antigens/infections or vaccines, providing enhanced resistance to unrelated pathogens or reduced infection severity. For example, individuals vaccinated with BCG to protect against tuberculosis were also protected from malaria and SARS-CoV-2 infections. Epigenetic modifications such as histone acetylation and metabolic reprogramming (e.g. shift towards glycolysis) and their inter-linked regulations are the key factors underpinning the immune activation of trained cells. The integrated metabolic and epigenetic rewiring generates sufficient metabolic intermediates, which is crucial to meet the energy demand required to produce proinflammatory and antimicrobial responses by the trained cells. These factors also determine the efficacy and durability of trained immunity. Importantly, the signaling pathways and regulatory molecules of trained immunity can be harnessed as potential targets for developing novel intervention strategies, such as better vaccines and immunotherapies against infectious (e.g., sepsis) and non-infectious (e.g., cancer) diseases. However, aberrant inflammation caused by inappropriate onset of trained immunity can lead to severe autoimmune pathological consequences, (e.g., systemic sclerosis and granulomatosis). In this review, we provide an overview of conventional innate and adaptive immunity and summarize various mechanistic factors associated with the onset and regulation of trained immunity, focusing on immunologic, metabolic, and epigenetic changes in myeloid cells. This review underscores the transformative potential of trained immunity in immunology, paving the way for developing novel therapeutic strategies for various infectious and non-infectious diseases that leverage innate immune memory.
Collapse
Affiliation(s)
| | - Selvakumar Subbian
- Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, United States
| |
Collapse
|
2
|
Kodila A, Franko N, Sollner Dolenc M. A review on immunomodulatory effects of BPA analogues. Arch Toxicol 2023; 97:1831-1846. [PMID: 37204436 PMCID: PMC10256647 DOI: 10.1007/s00204-023-03519-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 05/11/2023] [Indexed: 05/20/2023]
Abstract
Bisphenol A (BPA) is a known endocrine disruptor found in many consumer products that humans come into contact with on a daily basis. Due to increasing concerns about the safety of BPA and the introduction of new legislation restricting its use, industry has responded by adopting new, less studied BPA analogues that have similar polymer-forming properties. Some BPA analogues have already been shown to exhibit effects similar to BPA, for example, contributing to endocrine disruption through agonistic or antagonistic behaviour at various nuclear receptors such as estrogen (ER), androgen (AR), glucocorticoid (GR), aryl hydrocarbon (AhR), and pregnane X receptor (PXR). Since the European Food Safety Authority (EFSA) issued a draft re-evaluation of BPA and drastically reduced the temporary tolerable daily intake (t-TDI) of BPA from 4 mg/kg body weight/day to 0.2 ng/kg body weight/day due to increasing concern about the toxic properties of BPA, including its potential to disrupt immune system processes, we conducted a comprehensive review of the immunomodulatory activity of environmentally abundant BPA analogues. The results of the review suggest that BPA analogues may affect both the innate and acquired immune systems and can contribute to various immune-mediated conditions such as hypersensitivity reactions, allergies, and disruption of the human microbiome.
Collapse
Affiliation(s)
- Anja Kodila
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia
| | - Nina Franko
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia
| | - Marija Sollner Dolenc
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia.
| |
Collapse
|
3
|
Jain R, Jain A, Jain S, Thakur SS, Jain SK. Linking bisphenol potential with deleterious effect on immune system: a review. THE NUCLEUS 2022. [DOI: 10.1007/s13237-022-00383-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Wei X, Zhang L, Zhang R, Wu R, Petitte JN, Hou Y, Si D, Ahmad B, Guo H, Zhang M, Cheng Q, Tong Y. Targeting the TLR2 Receptor With a Novel Thymopentin-Derived Peptide Modulates Immune Responses. Front Immunol 2021; 12:620494. [PMID: 34122400 PMCID: PMC8191578 DOI: 10.3389/fimmu.2021.620494] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Accepted: 05/07/2021] [Indexed: 11/17/2022] Open
Abstract
The innate and adaptive immune systems act in concert to protect us from infectious agents and other harmful substances. As a state of temporary or permanent immune dysfunction, immunosuppression can make an organism more susceptible to infection, organ injury, and cancer due to damage to the immune system. It takes a long time to develop new immunomodulatory agents to prevent and treat immunosuppressive diseases, with slow progress. Toll-like receptor 2 (TLR2) agonists have been reported as potential immunomodulatory candidates due to their effective activation of immune responses. It has been demonstrated that thymopentin (TP5) could modulate immunity by binding to the TLR2 receptor. However, the fairly short half-life of TP5 greatly reduces its pharmacological potential for immunosuppression therapy. Although peptide cathelicidin 2 (CATH2) has a long half-life, it shows poor immunomodulatory activity and severe cytotoxicity, which seriously hampers its clinical development. Peptide hybridization is an effective approach for the design and engineering of novel functional peptides because hybrid peptides combine the advantages and benefits of various native peptides. In this study, to overcome all these challenges faced by the parental peptides, six hybrid peptides (CaTP, CbTP, CcTP, TPCa, TPCb, and TPCc) were designed by combining the full-length TP5 with different active fragments of CATH2. CbTP, the most potent TLR2 agonist among the six hybrid peptides, was effectively screened through in silico analysis and in vitro experiments. The CbTP peptide exhibited lower cytotoxicity than either CATH2 or TP5. Furthermore, the immunomodulatory effects of CbTP were confirmed in a CTX-immunosuppressed mouse model, which showed that CbTP has increased immunopotentiating activity and physiological stability compared to the parental peptides. CbTP successfully inhibited immunosuppression and weight loss, increased immune organ indices, and improved CD4+/CD8+ T lymphocyte subsets. In addition, CbTP significantly increased the production of the cytokine TNF-α and IL-6, and the immunoglobulins IgA, IgM, and IgG. The immunoenhancing effects of CbTP were attributed to its TLR2-binding activity, promoting the formation of the TLR2 cluster, the activation of the TLR2 receptor, and thus activation of the downstream MyD88-NF-кB signaling pathway.
Collapse
Affiliation(s)
- Xubiao Wei
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Lulu Zhang
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Rijun Zhang
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Rujuan Wu
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - James N Petitte
- Prestage Department of Poultry Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC, United States
| | - Yanfei Hou
- School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
| | - Dayong Si
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Baseer Ahmad
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Henan Guo
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Manyi Zhang
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Qiang Cheng
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - Yucui Tong
- Laboratory of Feed Biotechnology, State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
| |
Collapse
|
5
|
Nowak K, Jabłońska E, Ratajczak-Wrona W. Immunomodulatory effects of synthetic endocrine disrupting chemicals on the development and functions of human immune cells. ENVIRONMENT INTERNATIONAL 2019; 125:350-364. [PMID: 30743143 DOI: 10.1016/j.envint.2019.01.078] [Citation(s) in RCA: 131] [Impact Index Per Article: 26.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 01/27/2019] [Accepted: 01/29/2019] [Indexed: 05/22/2023]
Abstract
Endocrine disrupting chemicals (EDCs) are added to food, cosmetics, plastic packages, and children's toys and have thus become an integral part of the human environment. In the last decade, there has been increasing interest in the effect of EDCs on human health, including their impact on the immune system. So far, researchers have proved that EDCs (e.g. bisphenols, phthalates, triclosan, phenols, propanil, tetrachlorodibenzo-p-dioxin, diethylstilbestrol, tributyltin (TBT), and parabens) affect the development, functions, and lifespan of immune cells (e.g., monocytes, neutrophils, mast cells, eosinophils, lymphocytes, dendritic cells, and natural killers). In this review, we have summarized the current knowledge of the multivariable influence of EDCs on immune cells and underlined the novel approach to EDC studies, including dose-dependent effects and low-dose effects. We discuss critically the possible relationship between exposure to EDCs and immunity related diseases (e.g. allergy, asthma, diabetes, and lupus). Moreover, based on the literature, we construct a model of possible mechanisms of EDC action on immune cells at cellular, molecular, and epigenetic levels.
Collapse
Affiliation(s)
- Karolina Nowak
- Department of Immunology, Medical University of Bialystok, Poland.
| | - Ewa Jabłońska
- Department of Immunology, Medical University of Bialystok, Poland
| | | |
Collapse
|
6
|
Nazi̇k H, Turhan M, Koca TT, Mülayim MK, Öztürk P, Nazi̇k S. Arıcılarda Arı Ürünlerine Maruziyet ile Alerji, İnflamasyon ve Enfeksiyon İlişkili Durumların Araştırılması. KAHRAMANMARAŞ SÜTÇÜ İMAM ÜNIVERSITESI TIP FAKÜLTESI DERGISI 2018. [DOI: 10.17517/ksutfd.399577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
7
|
Emami A, Tepper J, Short B, Yaksh TL, Bendele AM, Ramani T, Cisternas AF, Chang JH, Mellon RD. Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular. Int J Toxicol 2017; 37:4-27. [PMID: 29264927 DOI: 10.1177/1091581817741840] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
As the need for nasal, ocular, spinal, and articular therapeutic compounds increases, toxicology assessments of drugs administered via these routes play an important role in human safety. This symposium outlined the local and systemic evaluation to support safety during the development of these drugs in nonclinical models with some case studies. Discussions included selection of appropriate species for the intended route; conducting nonclinical studies that closely mimic the intended use with adequate duration; functional assessment, if deemed necessary; evaluation of local tissues with special histological staining procedure; and evaluations of safety margins based on local and systemic toxicity.
Collapse
Affiliation(s)
- Armaghan Emami
- 1 US Food and Drug Administration, Silver Spring, MD, USA
| | - Jeff Tepper
- 2 Tepper Nonclinical Consulting, San Carlos, CA, USA
| | - Brian Short
- 3 Brian Short Consulting, LLC, Trabuco Canyon, CA, USA
| | - Tony L Yaksh
- 4 Department of Anesthesiology, University of California, San Diego, La Jolla, CA, USA
| | | | | | | | - Jay H Chang
- 1 US Food and Drug Administration, Silver Spring, MD, USA
| | | |
Collapse
|
8
|
Willebrords J, Crespo Yanguas S, Maes M, Decrock E, Wang N, Leybaert L, Kwak BR, Green CR, Cogliati B, Vinken M. Connexins and their channels in inflammation. Crit Rev Biochem Mol Biol 2016; 51:413-439. [PMID: 27387655 PMCID: PMC5584657 DOI: 10.1080/10409238.2016.1204980] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Inflammation may be caused by a variety of factors and is a hallmark of a plethora of acute and chronic diseases. The purpose of inflammation is to eliminate the initial cell injury trigger, to clear out dead cells from damaged tissue and to initiate tissue regeneration. Despite the wealth of knowledge regarding the involvement of cellular communication in inflammation, studies on the role of connexin-based channels in this process have only begun to emerge in the last few years. In this paper, a state-of-the-art overview of the effects of inflammation on connexin signaling is provided. Vice versa, the involvement of connexins and their channels in inflammation will be discussed by relying on studies that use a variety of experimental tools, such as genetically modified animals, small interfering RNA and connexin-based channel blockers. A better understanding of the importance of connexin signaling in inflammation may open up towards clinical perspectives.
Collapse
Affiliation(s)
- Joost Willebrords
- Department of In Vitro Toxicology and
Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels,
Belgium; Joost Willebrords: + Tel: 32 2 477 45 87, Michaël Maes: Tel: +32 2
477 45 87, Sara Crespo Yanguas: Tel: +32 2 477 45 87
| | - Sara Crespo Yanguas
- Department of In Vitro Toxicology and
Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels,
Belgium; Joost Willebrords: + Tel: 32 2 477 45 87, Michaël Maes: Tel: +32 2
477 45 87, Sara Crespo Yanguas: Tel: +32 2 477 45 87
| | - Michaël Maes
- Department of In Vitro Toxicology and
Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels,
Belgium; Joost Willebrords: + Tel: 32 2 477 45 87, Michaël Maes: Tel: +32 2
477 45 87, Sara Crespo Yanguas: Tel: +32 2 477 45 87
| | - Elke Decrock
- Department of Basic Medical Sciences, Physiology Group, Ghent
University, De Pintelaan 185, 9000 Ghent, Belgium; Elke Decrock: Tel: +32 9 332 39
73, Nan Wang: Tel: +32 9 332 39 38, Luc Leybaert: Tel: +32 9 332 33 66
| | - Nan Wang
- Department of Basic Medical Sciences, Physiology Group, Ghent
University, De Pintelaan 185, 9000 Ghent, Belgium; Elke Decrock: Tel: +32 9 332 39
73, Nan Wang: Tel: +32 9 332 39 38, Luc Leybaert: Tel: +32 9 332 33 66
| | - Luc Leybaert
- Department of Basic Medical Sciences, Physiology Group, Ghent
University, De Pintelaan 185, 9000 Ghent, Belgium; Elke Decrock: Tel: +32 9 332 39
73, Nan Wang: Tel: +32 9 332 39 38, Luc Leybaert: Tel: +32 9 332 33 66
| | - Brenda R. Kwak
- Department of Pathology and Immunology and Division of Cardiology,
University of Geneva, Rue Michel-Servet 1, CH-1211 Geneva, Switzerland; Brenda R.
Kwak: Tel: +41 22 379 57 37
| | - Colin R. Green
- Department of Ophthalmology and New Zealand National Eye Centre,
University of Auckland, New Zealand; Colin R. Green: Tel: +64 9 923 61 35
| | - Bruno Cogliati
- Department of Pathology, School of Veterinary Medicine and Animal
Science, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva 87,
05508-270 São Paulo, Brazil; Bruno Cogliati: Tel: +55 11 30 91 12 00
| | - Mathieu Vinken
- Department of In Vitro Toxicology and
Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels,
Belgium; Joost Willebrords: + Tel: 32 2 477 45 87, Michaël Maes: Tel: +32 2
477 45 87, Sara Crespo Yanguas: Tel: +32 2 477 45 87
| |
Collapse
|
9
|
Wormald PJ. Editorial: the annual Institute for Scientific Information(ISI). Int Forum Allergy Rhinol 2014; 4:691-2. [PMID: 25182193 DOI: 10.1002/alr.21409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|